Levothyroxine

Pharmacologic Category

Thyroid Product

Dosing: Adult

Note: Levothyroxine is synthetic thyroxine (T4). Due to its prolonged half-life, levothyroxine steady-state concentrations are not achieved until ~6 weeks after therapy is initiated or dosage adjustment; therefore, the full effect at a given dose may not be apparent until then. Individual T4 requirements correlate better with lean body mass than total body weight (Santini 2005). Weight-based dosing may overestimate initial replacement doses in obese patients. Initial doses >200 mcg/day are rarely used, regardless of patient weight (Roos 2005; manufacturer's labeling).

Deceased organ donor management (hormonal resuscitation for the deceased organ donor) (off-label use):

Note: Data supporting benefit are conflicting; if given, guidelines suggest use in hemodynamically unstable donors and/or potential cardiac donors with decreased left ejection fraction (<45%) (MacDonald 2012; Novitzky 2014; Novitzky 2015; SCCM/ACCP/AOPO [Kotloff 2015]).

IV: Initial: 20 mcg bolus, followed by a continuous infusion of 10 mcg/hour; levothyroxine is usually given as part of combination hormone therapy with vasopressin, methylprednisolone, and insulin (Kumar 2016; SCCM/ACCP/AOPO [Kotloff 2015]).

Hypothyroidism:

Note: Dose is individualized according to clinical response and serum thyroid stimulating hormone (TSH) and/or free T4 concentrations (ATA [Jonklaas 2014]; Ross 2019e). Average dose is ~1.6 mcg/kg/day; range of required doses is wide and varies from 50 to ≥200 mcg/day (Ross 2019e). Maintenance doses >300 mcg/day are rarely required; in patients who require high doses (eg, >2 mcg/kg/day), consider poor compliance, malabsorption, and/or drug interactions (Ross 2019e).

Primary hypothyroidism: Note: Adjust initial dose by 12 to 25 mcg/day every 3 to 6 weeks based on clinical response and serum TSH and/or free T4 concentrations until TSH is normalized at a stable dose for ≥6 weeks.

Patients ≤60 years of age without evidence of coronary heart disease: Oral: Initial: 1.6 mcg/kg/day (ATA [Jonklaas 2014]; Ross 2019e).

Patients >60 years of age without evidence of coronary heart disease: Oral: Initial: 25 to 50 mcg once daily (AACE/ATA Garber 2012]; ATA [Jonklaas 2014]); Ross 2019e).

Patients with coronary heart disease: Oral: Initial: 12.5 to 50 mcg once daily (AACE/ATA [Garber 2012]; ATA [Jonklaas 2014]; Ross 2019e); monitor for the onset of cardiac symptoms (eg, angina) and decrease the dose if needed (AACE/ATA [Garber 2012]). Note: Patients without other significant comorbidities who have had recent successful interventions to treat ischemia (eg, coronary artery bypass grafting or coronary artery stenting) can initially receive up to 80% of the weight-based dose (1.6 mcg/kg/day) (Ross 2019e).

Pregnant patients: Note: Thyroid function tests should be interpreted using population-based, trimester-specific reference ranges for TSH and assay method- and trimester-specific reference ranges for serum free T4 (ATA [Alexander 2017]).

Preexisting hypothyroidism in women receiving levothyroxine prenatally: Patients with suspected or confirmed pregnancy: Oral: Immediately increase the current dose by ~30% (eg, administer 2 additional tablets weekly of the current dose) and adjust dose as needed every 4 weeks (ATA [Alexander 2017]).

Newly diagnosed overt hypothyroidism: Oral: Initial: 1.6 mcg/kg/day; adjust dose by ~25 mcg/day as needed every 4 to 6 weeks to restore patient to euthyroidism as soon as possible (ACOG 2015; ATA [Alexander 2017]; Ross 2019b).

Newly diagnosed subclinical hypothyroidism (off-label use):

Note: The decision to treat is based on the degree of TSH elevation and the presence or absence of thyroid peroxidase antibodies. If treated, goal is to restore euthyroidism (ATA [Alexander 2017]). Some experts treat pregnant women with subclinical hypothyroidism (defined as TSH above trimester-specific normal reference range [or above 4 milliunits/L if trimester-specific range unavailable] with normal free T4), regardless of thyroid peroxidase antibody status, and would consider treatment in select pregnant women with TSH levels between 2.6 and 4 milliunits/L based on the presence or absence of thyroid peroxidase antibodies, clinical factors, and patient preferences (Ross 2019b).

Oral: Initial: 1 mcg/kg/day or 50 mcg daily; adjust dose by ~12 to 25 mcg/day as needed every 4 weeks (ATA [Alexander 2017]; Ross 2019b).

Postpartum dosage adjustment: In patients treated prenatally for hypothyroidism, decrease the dose to preconception levels following delivery. In patients who were initiated on levothyroxine during pregnancy, evaluate the need for continued treatment (ATA [Alexander 2017]).

Subclinical hypothyroidism (off-label use):

Note: Treatment may be considered in select patients with TSH levels above normal reference range depending on degree of TSH abnormality, age, and symptoms (Feller 2018; Ross 2019d). In patients with TSH >10 milliunits/L, treatment is generally warranted, whereas benefit of treatment in asymptomatic patients with TSH levels between 4.5 and 10 milliunits/L is not well established (AACE/ATA [Garber 2012]; Ross 2019d).

Adults <50 years of age without coronary heart disease: Oral: Initial: 1.5 mcg/kg/day (ETA [Pearce 2013]; Ross 2019d).

Patients with coronary heart disease or ≥50 years of age: Oral: Initial: 25 to 50 mcg once daily (ETA [Pearce 2013]; Ross 2019d).

Dosage adjustment: Initial dose is adjusted by 12 to 25 mcg/day once every 6 weeks until targeted TSH is achieved with a stable dose for ≥6 weeks; thereafter assess TSH level annually (Ross 2019d).

Postpartum thyroiditis (hypothyroid phase):

Note: Treat women who are symptomatic or planning another pregnancy (ATA [Alexander 2017]; Stagnaro-Green 2011); some experts will treat asymptomatic patients who are breastfeeding (ATA [Alexander 2017]) or who have a TSH >10 milliunits/L (Burman 2019). Dosing recommendations and duration of treatment are not standardized; treatment is individualized according to clinical assessment:

Oral: Initial: 25 to 75 mcg once daily (ACOG 2015); alternatively, some experts suggest an initial dose of 50 to 100 mcg once daily (Burman 2019). Adjust dose as needed once every 4 to 6 weeks until TSH is normalized. Tapering of the dose with a goal of discontinuation, if possible, may begin after 6 to 12 months of treatment (ACOG 2015; Stagnaro-Green 2011).

Secondary hypothyroidism:

Note: Patients with secondary (central) hypothyroidism should undergo assessment of their pituitary-adrenal function prior to initiation of therapy. If shown to have adrenal insufficiency, concomitant administration of a glucocorticoid is recommended to prevent an adrenal crisis (ATA [Jonklaas 2014]; Ross 2019a).

Oral: Initial: 1.6 mcg/kg/day; some experts initiate treatment at a lower dose in older patients or patients with underlying coronary heart disease (Ross 2019a). Adjust dose based on clinical response and serum free T4 concentrations. TSH cannot be used to monitor therapy (ATA [Jonklaas 2014]; Ross 2019a).

Myxedema coma:

IV: Initial loading dose of 200 to 400 mcg as a slow bolus; followed by a daily replacement dose of 50 to 100 mcg until the patient improves clinically and can transition to oral therapy; consider doses on the lower end of the dosing range for smaller or older patients and those with a history of or at risk for coronary disease or arrhythmia; concomitant glucocorticoid therapy is required until the possibility of coexisting adrenal insufficiency is excluded (ATA [Jonklaas 2014]; Ross 2019c); some experts administer liothyronine (T3) concomitantly with levothyroxine (T4) (Ross 2019c).

TSH suppression:

Well-differentiated thyroid cancer (papillary and follicular): Dosage is highly individualized as the degree of TSH suppression is initially based on the risk of disease recurrence using a staging system such as the American Thyroid Association (ATA) risk-of-recurrence stratification system (ATA [Haugen 2016]; Tuttle 2019). Long-term TSH suppression goals should account for response to therapy, risk of recurrent disease, age, and comorbid conditions (ATA [Haugen 2016]).

Oral: Initial: 1.6 to 2 mcg/kg/day immediately postsurgery (Tuttle 2019); adjust dose as needed in 6 weeks based on TSH suppression goals (ATA [Haugen 2016]):

Note: For patients with ATA low-risk disease whose initial surgery was a lobectomy, some experts initiate therapy at a later time when TSH concentrations or disease status dictate a need (ATA [Haugen 2016]; Lee 2015; Tuttle 2019).

Benign solitary nodules and nontoxic multinodular goiter: Routine use of levothyroxine for TSH suppression is not recommended in euthyroid patients with benign thyroid nodules in iodine-sufficient geographic areas. In patients deemed appropriate candidates, treatment should never be fully suppressive (ie, do not target TSH <0.1 milliunits/L) (AACE/ACE/AME [Gharib 2016]; ATA [Haugen 2016]).

IV/IM replacement in patients who are temporarily unable to receive oral therapy:

IM (off-label route), IV (off-label use): Administer ~75% to 80% of the established oral dose once daily (ATA [Jonklaas 2014]; Manzullo 2019).

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Obesity: Adult

Individual T4 requirements correlate better with lean body weight than total body weight (Santini 2005); weight-based dosing may overestimate initial replacement doses in obese patients; as such, dosing in obesity must be individualized.

Dosing: Adjustment for Toxicity: Adult

Cardiac symptoms (onset or worsening): Manufacturer labeling recommends reducing dosage or withholding therapy for 7 days and then resuming therapy at reduced dosage. Specific dosing recommendations are not provided.

Dosing: Pediatric

Note: Doses should be adjusted based on clinical response and laboratory parameters; on a weight basis, dosing is higher in infants and children than adults due to the higher metabolic clearance.

Hypothyroidism (acquired or congenital): Note: Hyperactivity in older children may be minimized by starting at one-quarter (25%) of the recommended dose and increasing each week by that amount until the full dose is achieved (4 weeks).

Oral:

1 to 3 months: 10 to 15 mcg/kg/dose once daily; in severe cases of hypothyroidism (serum T4 <5 mcg/dL), initiating at higher doses (12 to 17 mcg/kg/dose) may be necessary (AAP 2006; ATA [Jonklaas 2014]; Léger 2014; Selva 2002).

>3 to 6 months: 8 to 10 mcg/kg/dose once daily

>6 to 12 months: 6 to 8 mcg/kg/dose once daily

1 to 5 years: 5 to 6 mcg/kg/dose once daily

6 to 12 years: 4 to 5 mcg/kg/dose once daily

>12 years with incomplete growth and puberty: 2 to 3 mcg/kg/dose once daily

Adolescents with growth and puberty complete: 1.6 mcg/kg/dose once daily; adjust dose by 12.5 to 25 mcg/day every 4 to 6 weeks as needed. Usual doses are ≤200 mcg/day (range: 100 to 125 mcg/day [70 kg adult]); doses ≥300 mcg/day are rare (consider poor compliance, malabsorption, and/or drug interactions).

Cardiac disease: Note: Lower initial doses are recommended.

Infants and Children: Initial: ~50% of target replacement dose; increase after 2 weeks based on free thyroxine levels (Léger 2014)

Adolescents with growth and puberty complete: Initial: 12.5 to 25 mcg/day; adjust dose by 12.5 to 25 mcg increments at 6- to 8-week intervals as needed

IV: Note: The relative bioavailability of injectable and oral levothyroxine has not been established; use caution when switching patients from oral to IV as accurate dosing conversions have not been established. Infants, Children, and Adolescents: ~75% to 80% of the oral dose has been suggested by guidelines (ATA [Jonklaas 2014]; Léger 2014).

Thyroid-stimulating hormone (TSH) suppression in well differentiated thyroid cancer (papillary): Infants, Children, and Adolescents: Oral: Highly individualized; doses >2 mcg/kg/day may be needed to suppress TSH to <0.1 milliunits/L in high-risk tumors; for intermediate-risk tumors, initial TSH suppression to 0.1 to 0.5 milliunits/L is recommended; for low-risk tumors, TSH may be maintained at 0.5 to 1 milliunits/L (ATA [Francis 2015]).

Organ donor management in brain-dead patients (hormone replacement therapy) (Nakagawa 2008; Zuppa 2004): IV:

Infants <6 months: Initial: 5 mcg/kg bolus dose, followed by 1.4 mcg/kg/hour infusion

Infants 6 to 12 months: Initial: 4 mcg/kg bolus dose, followed by 1.3 mcg/kg/hour infusion

Children 1 to 5 years: Initial: 3 mcg/kg bolus dose, followed by 1.2 mcg/kg/hour infusion

Children 6 to 12 years: Initial: 2.5 mcg/kg bolus dose, followed by 1 mcg/kg/hour infusion

Children ≥12 years and Adolescents ≤16 years: Initial: 1.5 mcg/kg bolus dose, followed by 0.8 mcg/kg/hour infusion

Adolescents >16 years: Initial: 0.8 mcg/kg bolus dose, followed by 0.8 mcg/kg/hour infusion

Dosing: Renal Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Use: Labeled Indications

Oral:

Hypothyroidism: Replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology. Specific indications include primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism. Note: Levothyroxine monotherapy is recommended as the preferred thyroid preparation for the treatment of hypothyroidism (ATA [Jonklaas 2014]; ES [Fleseriu 2016]).

Pituitary thyrotropin-stimulating hormone suppression: An adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Injectable: Treatment of myxedema coma

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

Deceased organ donor management (hormonal resuscitation for the deceased organ donor)Level of Evidence [C, G]

Data from retrospective cohort studies of brain-dead donors who successfully donated organs suggest that the use of levothyroxine given concomitantly with vasopressin, methylprednisolone, and a continuous infusion of insulin (goal blood glucose: 120 to 180 mg/dL) may be beneficial for hemodynamically unstable brain-dead donors to increase the quantity and quality of organs available for transplantation Ref; however, data supporting benefit are conflicting Ref.

Based on a Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations consensus statement, the use of levothyroxine (or liothyronine) (in combination with vasopressin, methylprednisolone, and insulin) should be considered for hemodynamically unstable donors or potential cardiac donors with reduced left ventricular ejection fraction (<45%) Ref.

Subclinical hypothyroidismLevel of Evidence [C, G]

Nonpregnant patients:

Data from a meta-analysis do not support the routine use of levothyroxine in nonpregnant adults with subclinical hypothyroidism Ref. Clinical experience suggests treatment be considered in select patients depending on degree of TSH abnormality, age, and symptoms Ref.

Based on the American Association of Clinical Endocrinologists/American Thyroid Association (AACE/ATA) clinical practice guidelines for hypothyroidism in adults and the European Thyroid Association (ETA) guideline for management of subclinical hypothyroidism, thyroid replacement with levothyroxine is recommended in select patients with subclinical hypothyroidism (persistently elevated TSH with free T4 within normal range) Ref.

Pregnant patients:

Clinical experience suggests treatment with levothyroxine for pregnant women with newly diagnosed subclinical hypothyroidism (defined as TSH above trimester-specific normal reference range [or above 4 milliunits/L if trimester-specific range unavailable] with normal free T4), regardless of thyroid peroxidase antibody status. Clinical experience also suggests treatment be considered in select pregnant women with TSH levels between 2.6 and 4 milliunits/L based on the presence or absence of thyroid peroxidase antibodies, clinical factors, and patient preferences Ref.

Based on the ATA guidelines for the diagnosis and management of thyroid disease during pregnancy and the postpartum, levothyroxine is recommended for select pregnant patients with subclinical hypothyroidism depending on the degree of TSH abnormality and presence or absence of thyroid peroxidase antibodies Ref.

Level of Evidence Definitions

Level of Evidence Scale

Class and Related Monographs

Thyroid Hormones

Clinical Practice Guidelines

Hypothyroidism:

ATA/AACE, “Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association.” 2012

American Thyroid Association Task Force on Thyroid Hormone Replacement, “Guidelines for the Treatment of Hypothyroidism.” 2014

European Thyroid Association, “2013 ETA Guideline: Management of Subclinical Hypothyroidism.” 2013

Hypopituitarism:

Endocrine Society, “Hormonal Replacement in Hypopituitarism in Adults,” 2016

Thyroid Nodules and Differentiated Thyroid Cancer:

AACE/AAES Medical/Surgical Guidelines for Clinical Practice: Management of Thyroid Carcinoma, May/June 2001

AACE/ACE/AME Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules-2016 Update

American Thyroid Association (ATA), “Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer,” 2016

National Comprehensive Cancer Network® (NCCN), Clinical Practice Guidelines in Oncology™, Thyroid

Administration: IM

May be administered intramuscularly when oral administration is not feasible (off-label route)

Administration: IV

May be administered by IV injection at a maximum rate of 100 mcg/minute.

Cadaveric organ recovery (hormonal resuscitation) (off-label use): After IV bolus administration, may administer as a continuous infusion (Salim 2007).

Administration: Oral

Administer consistently in the morning on an empty stomach, at least 30 to 60 minutes before food. Alternatively, may consistently administer at night 3 to 4 hours after the last meal (AACE/ATA [Garber 2012]; ATA [Jonklaas 2014]). Do not administer within 4 hours of calcium- or iron-containing products or bile acid sequestrants.

Capsule: Must be swallowed whole; do not cut, crush, or chew.

Solution (Tirosint): May administer undiluted or diluted in water only (do not dilute with any other liquid); if administering undiluted, squeeze contents of single unit-dose ampule into mouth or onto a spoon and administer immediately. If diluting with water, squeeze contents of ampule into a glass or cup, stir, and then administer entire contents immediately. Rinse glass or cup with additional water and administer contents to ensure entire dose is consumed.

Tablet: Administer with a full glass of water (choking, gagging, and dysphagia have been reported with some formulations). May be crushed and suspended in 5 to 10 mL of water; suspension should be used immediately.

Administration: Other

Nasogastric tube: Bioavailability of levothyroxine (crushed tablets suspended in water) is reduced if administered with enteral tube feeds. Since holding feedings for at least 1 hour before and after levothyroxine administration may not completely resolve the interaction, an increase in dose (eg, additional 25 mcg) may be necessary (Dickerson 2010). Tirosint oral solution product labeling does not provide recommendations regarding nasogastric administration.

Administration: Pediatric

Oral: Administer consistently on an empty stomach 30 to 60 minutes prior to breakfast. Alternatively, may consistently administer at night 3 to 4 hours after the last meal (ATA [Jonklaas 2014]). If administration on an empty stomach poses a challenge, particularly in infants and small children, it may be administered with food to improve adherence and consistency of administration (Zeitler 2010). Do not administer within 4 hours of other medications known to interfere with levothyroxine absorption (eg, calcium- or iron-containing products or bile acid sequestrants).

Capsules: Children ≥6 years and Adolescents: Must be swallowed whole; do not cut, crush, or attempt to dissolve capsules in water to prepare a suspension.

Solution (Tirosint-SOL): May administer undiluted or diluted in water only (do not dilute with any other liquid).

Undiluted: Squeeze contents of single unit-dose ampule into mouth or onto a spoon and administer immediately.

Dilution with water: Squeeze contents of ampule into a glass or cup containing water, stir, and then administer entire contents immediately. Rinse glass or cup with additional water and administer contents to ensure entire dose is consumed.

Tablets: Administer with a full glass of water (choking, gagging, and dysphagia has been reported with some formulations). For infants and children who cannot swallow tablet whole, crush tablet and mix with small amount (5 to 10 mL) of water, breast milk, or non-soy-based formula and use immediately (AAP 2006; ATA [Jonklaas 2014]; Léger 2014).

Nasogastric tube: Bioavailability of levothyroxine (crushed tablets suspended in water) is reduced if administered with enteral tube feeds. Since holding feedings may not be appropriate for some patients and holding feedings for at least 1 hour before and after levothyroxine administration may not completely resolve the interaction, an increase in dose (eg, additional 25 mcg in adults) may be necessary (Dickerson 2010).

Parenteral:

IV: Administer IV over 2 to 3 minutes; for organ donor management in brain-dead patients, the IV bolus is followed by continuous IV infusion (Nakagawa 2008; Zuppa 2004)

IM: May be administered intramuscularly when oral administration is not feasible (Levothyroxine injection Canadian product labeling 2017)

Storage/Stability

Capsules and tablets: Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Protect from heat, light, and moisture.

Oral solution (Tirosint): Store in original container (closed aluminum pouch) at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Keep ampules in pouch until ready to use; after opening the pouch, all ampules in the pouch should be used within 15 days.

Injection: Store at 20°C to 25°C (68°F to 77°F). Protect from light.

Additional stability data:

Stability in polypropylene syringes (100 mcg/mL in NS) at 5°C ± 1°C is 7 days (Gupta 2000).

Stability in latex-free, PVC minibags protected from light and stored at 15°C to 30°C (59°F to 86°F) was 12 hours for a 2 mcg/mL concentration or 18 hours for a 0.4 mcg/mL concentration in NS. May be exposed to light; however, stability time is significantly reduced, especially for the 2 mcg/mL concentration (Strong 2010).

Preparation for Administration: Adult

For products requiring further dilution, reconstitute vial for injection with 5 mL NS. Reconstituted concentrations for the 100 mcg, 200 mcg, and 500 mcg vials are 20 mcg/mL, 40 mcg/mL, and 100 mcg/mL, respectively. Shake well and use immediately after reconstitution (manufacturer labeling suggests reconstituted vial is stable for 4 hours); discard any unused portions.

Preparation for Administration: Pediatric

Parenteral: Reconstitute vial for injection with 5 mL NS. Final concentration is dependent upon vial size; concentrations for the 100 mcg, 200 mcg, and 500 mcg vials are 20 mcg/mL, 40 mcg/mL, and 100 mcg/mL, respectively. Shake well and use immediately after reconstitution (manufacturer labeling suggests reconstituted vial is stable for 4 hours); discard any unused portions.

Compatibility

See Trissel’s IV Compatibility Database

Open Trissel's IV Compatibility

Extemporaneously Prepared

Note: A levothyroxine oral solution (multiple concentrations) is commercially available (Tirosint-SOL).

25 mcg/mL Oral Suspension

A 25 mcg/mL oral suspension may be made with tablets and 40 mL glycerol. Crush twenty-five 100 mcg levothyroxine tablets in a mortar and reduce to a fine powder. Add small portions of glycerol and mix to a uniform suspension. Transfer to a calibrated 100 mL amber bottle; rinse the mortar with about 10 mL of glycerol and pour into the bottle; repeat until all 40 mL of glycerol is used. Add quantity of water sufficient to make 100 mL. Label "shake well" and "refrigerate". Stable for 8 days refrigerated.

Boulton DW, Fawcett JP, and Woods DJ, "Stability of an Extemporaneously Compounded Levothyroxine Sodium Oral Liquid," Am J Health Syst Pharm, 1996, 53(10):1157-61.[PubMed 8734676]

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to add thyroid hormone to the body.

• It is used to manage thyroid cancer.

• It may be given to you for other reasons. Talk with the doctor.

Frequently reported side effects of this drug

• Hair loss

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Chest pain

• Fast heartbeat

• Abnormal heartbeat

• Headache

• Dizziness

• Passing out

• Vision changes

• Shortness of breath

• Loss of strength and energy

• Lack of appetite

• Increased appetite

• Excessive weight gain or loss

• Swelling of arms or legs

• Diarrhea

• Abdominal cramps

• Vomiting

• Irritability

• Anxiety

• Emotional instability

• Tremors

• Trouble sleeping

• Temperature sensitivity

• Sweating a lot

• Muscle cramps

• Muscle weakness

• Flushing

• Bone pain

• Menstrual irregularities

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

Administration issues:

Other safety concerns:

Contraindications

Injection: Uncorrected adrenal insufficiency; consider contraindications for oral therapy if using as a temporary substitute for oral treatment (off-label use) in patients with chronic hypothyroidism.

Oral: Uncorrected adrenal insufficiency; hypersensitivity to glycerol (Tirosint oral solution); Note: Product labels may vary; also consult product labels. Reported hypersensitivity to levothyroxine or any component of the formulation is not considered an absolute contraindication (ATA [Jonklaas 2014]); refer to Warnings/Precautions.

Canadian labeling: Additional contraindications (not in US labeling): Untreated subclinical thyrotoxicosis, overt thyrotoxicosis of any etiology, acute myocardial infarction, acute myocarditis, or acute pancarditis

Warnings/Precautions

Disease-related concerns:

• Adrenal insufficiency: Use with caution in patients with adrenal insufficiency; symptoms may be exaggerated or aggravated. Treatment with glucocorticoids should precede levothyroxine therapy in patients with adrenal insufficiency. Use is contraindicated in patients with uncorrected adrenal insufficiency.

• Benign thyroid nodules: Appropriate use: Routine use of T4 for thyroid stimulating hormone (TSH) suppression is not recommended in patients with benign thyroid nodules. Treatment should never be fully suppressive (TSH <0.1 milliunits/L) (AACE/ACE/AME [Gharib 2016]; ATA [Haugen 2016]).

- Use of T4 may be considered in association with iodine supplementation only in young patients residing in iodine-deficient areas with small thyroid nodules and no evidence of functional autonomy (AACE/ACE/AME [Gharib 2016]).

- Use should be avoided in postmenopausal women, elderly patients, patients with cardiovascular disease, osteoporosis, large thyroid nodules or long-standing goiters, or low-normal TSH levels (AACE/ACE/AME [Gharib 2016]).

• Cardiovascular disease: Use with caution and reduce dosage in patients with cardiovascular disease; patients with developing or worsening cardiac symptoms should have their dose reduced or therapy withheld for 7 days and then resumed at a reduced dose. Chronic hypothyroidism predisposes patients to coronary artery disease; monitor patients closely for development of cardiac ischemia. Similarly, patients with heart failure and hypothyroidism should be closely followed.

• Diabetes: Use with caution in patients with diabetes mellitus (may worsen glycemic control) and diabetes insipidus (thyroid hormone increases glomerular filtration rate and downregulates aquaporin channels in the renal tubules, which could affect urinary output) (Mariani 2012).

• Osteoporosis: Long-term therapy can decrease bone mineral density and appears to be dose-related (Schneider 1994). Postmenopausal women and women using suppressive doses should receive the lowest dose necessary for clinical response.

• Subacute thyroiditis: Transient and mild hypothyroidism during the recovery phase of subacute thyroiditis often can be managed without treatment; levothyroxine therapy may be required in patients with overt and clinical hypothyroidism (Farwell 2013).

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Special populations:

• Elderly: Use with caution; suppressed TSH levels may increase risk of atrial fibrillation and mortality secondary to cardiovascular disease (Gharib 2016; Parle 2001). Increase dose slowly and monitor for signs/symptoms of angina.

Dosage form specific issues:

• Product interchangeability: Switching between different levothyroxine products may result in variations in the administered dose and altered TSH values and is not generally recommended; if formulations are changed, close monitoring of TSH is recommended (ATA [Jonklaas 2014]). Pediatric patients with congenital hypothyroidism may be more sensitive to changes in formulation (Carswell 2013).

Other warnings/precautions:

• Hypersensitivity: Patients with reported hypersensitivity to levothyroxine may be managed with dose reductions and slow titration, by switching formulations or products, or referral to an allergist (ATA [Jonklaas 2014]).

• Weight reduction (off-label use): [US Boxed Warning]: Thyroid supplements are ineffective and potentially toxic when used for the treatment of obesity or for weight reduction, especially in euthyroid patients. High doses may produce serious or even life-threatening toxic effects, particularly when used with some anorectic drugs (eg, sympathomimetic amines). Levothyroxine, either alone or with other concomitant therapeutic agents, should not be used for the treatment of obesity or for weight loss.

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

Elderly do not have a change in serum thyroxine associated with aging; however, plasma T3 concentrations are decreased 25% to 40% in the elderly. There is not a compensatory rise in thyrotropin suggesting that lower T3 is not reacted upon as a deficiency by the pituitary. This indicates a slightly lower than normal starting dosage of thyroid hormone replacement is usually sufficient in elderly patients than in younger adult patients with subsequent dose increases based on TSH levels. TSH must be monitored since insufficient thyroid replacement (elevated TSH) is a risk for coronary artery disease and excessive replacement (low TSH) may cause signs of hyperthyroidism and excessive bone loss. Some clinicians suggest levothyroxine is the drug of choice for replacement therapy. The once-daily dosing of levothyroxine makes it an ideal choice than other thyroid preparations which may require more frequent dosing and offer no additional benefits over levothyroxine.

Warnings: Additional Pediatric Considerations

Overtreatment may result in craniosynostosis in infants and premature closure of epiphyses in children; monitor use closely. In neonates and infants, cardiac overload, arrhythmias, and aspiration from avid suckling may occur during initiation of therapy (eg, first 2 weeks); monitor closely.

Pregnancy Considerations

Levothyroxine has not been shown to increase the risk of congenital abnormalities or miscarriage. Maternal hypothyroidism, however, can be associated with adverse effects in the mother and fetus, including spontaneous abortion, stillbirth, premature birth, low birth weight, impaired neurocognitive development in the off-spring, abruptio placentae, gestational hypertension, and preeclampsia (ACOG 148 2015; ATA [Alexander 2017]).

Thyroid replacement therapy minimizes the risk of adverse pregnancy outcomes in females with overt hypothyroidism and treatment is recommended during pregnancy (ACOG 148 2015; ATA [Alexander 2017]). Levothyroxine is the preferred treatment of maternal hypothyroidism; other agents should not be used in pregnant females (ACOG 148 2015; ATA [Alexander 2017]; ES [De Groot 2012]). Levothyroxine is also recommended in some cases of subclinical hypothyroidsim during pregnancy, and overt hypothyroidism in females with postpartum thyroiditis (ACOG 148 2015; ATA [Alexander 2017]; ES [De Groot 2012]).

Due to alterations of endogenous maternal thyroid hormones, hypothyroid patients treated with levothyroxine prior to pregnancy require a dose increase as soon as pregnancy is confirmed (ATA [Alexander 2017]; ES [De Groot 2012]). Close monitoring of pregnant patients is recommended (ATA [Alexander 2017]).

Overt hypothyrodism increases the risk of infertility; treatment with levothyroxine is recommended to normalize thyroid function in infertile females with overt hypothyroidism who desire pregnancy. Levothyroxine may also be used in infertile females with subclinical hypothyrodism using assisted reproductive techniques (ATA [Alexander 2017]).

Breast-Feeding Considerations

Levothyroxine is present in breast milk (limited data).

Levothyroxine was not found to cause adverse events to the infant or mother during breastfeeding (Ito 1993). Adequate thyroid hormone concentrations are required to maintain normal lactation.

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. The World Health Organization considers levothyroxine to be compatible with breastfeeding (WHO 2002).

Lexicomp Pregnancy & Lactation, In-Depth

• Levothyroxine

Briggs' Drugs in Pregnancy & Lactation

• Levothyroxine

Adverse Reactions

Adverse reactions are primarily those of hyperthyroidism due to therapeutic overdosage.

Frequency not defined:

Cardiovascular: Angina pectoris, cardiac arrhythmia, cardiac failure, flushing, increased blood pressure, increased pulse, myocardial infarction, palpitations, tachycardia

Central nervous system: Anxiety, emotional lability, fatigue, headache, heat intolerance, hyperactivity, insomnia, irritability, myasthenia, nervousness, pseudotumor cerebri (children)

Dermatologic: Alopecia, diaphoresis, skin rash

Endocrine & metabolic: Goiter (exophthalmic; IV), menstrual disease, weight loss

Gastrointestinal: Abdominal cramps, diarrhea, increased appetite, vomiting

Genitourinary: Reduced fertility

Hepatic: Increased liver enzymes

Neuromuscular & skeletal: Decreased bone mineral density, muscle spasm, slipped capital femoral epiphysis (children), tremor

Respiratory: Dyspnea

Miscellaneous: Fever

<1%, postmarketing, and/or case reports: Dysgeusia (Syed 2016), seizure

* See Cautions in AHFS Essentials for additional information.

Allergy and Idiosyncratic Reactions

• Levothyroxine Allergy

Toxicology

• Thyroid Products

Metabolism/Transport Effects

None known.

Drug Interactions Open Interactions

Aluminum Hydroxide: May decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and aluminum hydroxide by at least 4 hours. Risk D: Consider therapy modification

Amezinium: Thyroid Products may enhance the stimulatory effect of Amezinium. Risk C: Monitor therapy

Amiodarone: May diminish the therapeutic effect of Thyroid Products. Risk C: Monitor therapy

Apalutamide: May diminish the therapeutic effect of Thyroid Products. Risk C: Monitor therapy

Bile Acid Sequestrants: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine. Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product. Risk D: Consider therapy modification

Calcium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral calcium polystyrene sulfonate and thyroid products (eg, levothyroxine) or administer calcium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral). Risk D: Consider therapy modification

Calcium Salts: May diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Risk D: Consider therapy modification

CarBAMazepine: May decrease the serum concentration of Thyroid Products. Risk C: Monitor therapy

Cardiac Glycosides: Thyroid Products may decrease the serum concentration of Cardiac Glycosides. Specifically, returning to a euthyroid state from a hypothyroid state may decrease the serum concentration of cardiac glycosides. Risk C: Monitor therapy

Ciprofloxacin (Systemic): May decrease the serum concentration of Thyroid Products. Risk C: Monitor therapy

Estrogen Derivatives: May diminish the therapeutic effect of Thyroid Products. Risk C: Monitor therapy

Fosphenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites. Risk C: Monitor therapy

Iron Preparations: May decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron preparations and levothyroxine by at least 4 hours. Separation of doses is not required with parenterally administered iron preparations or levothyroxine. Exceptions: Ferric Carboxymaltose; Ferric Derisomaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose. Risk D: Consider therapy modification

Lanthanum: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least two hours before or after lanthanum. Risk D: Consider therapy modification

Magnesium Salts: May decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and oral magnesium salts by at least 4 hours. Risk D: Consider therapy modification

Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron-containing multivitamins and levothyroxine by at least 4 hours. Risk D: Consider therapy modification

Orlistat: May decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and orlistat by a least 4 hours. Monitor patients closely for signs and symptoms of hypothyroidism. Risk D: Consider therapy modification

Patiromer: May decrease the serum concentration of Levothyroxine. Management: Administer oral levothyroxine at least 3 hours before or 3 hours after patiromer. Risk D: Consider therapy modification

Phenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites. Risk C: Monitor therapy

Piracetam: May enhance the adverse/toxic effect of Thyroid Products. Specifically, symptoms including confusion, irritability, and sleep disorder have been described during concomitant use. Risk C: Monitor therapy

Polaprezinc: May decrease the serum concentration of Levothyroxine. Risk D: Consider therapy modification

Raloxifene: May decrease the absorption of Levothyroxine. Risk D: Consider therapy modification

RifAMPin: May decrease the serum concentration of Thyroid Products. Risk C: Monitor therapy

Ritonavir: May diminish the therapeutic effect of Thyroid Products. Risk C: Monitor therapy

Selective Serotonin Reuptake Inhibitors: May diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased. Risk C: Monitor therapy

Semaglutide: May increase the serum concentration of Levothyroxine. Risk C: Monitor therapy

Sevelamer: May decrease the serum concentration of Levothyroxine. Management: Consider separating administration of sevelamer and levothyroxine by at least several hours whenever possible in order to decrease the risk of a significant interaction. Risk D: Consider therapy modification

Sodium Iodide I131: Thyroid Products may diminish the therapeutic effect of Sodium Iodide I131. Risk X: Avoid combination

Sodium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral sodium polystyrene sulfonate and thyroid products (e.g., levothyroxine) or administer sodium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral). Risk D: Consider therapy modification

Somatropin: May diminish the therapeutic effect of Thyroid Products. Risk C: Monitor therapy

Sucralfate: May decrease the serum concentration of Levothyroxine. Risk C: Monitor therapy

Sucroferric Oxyhydroxide: May decrease the serum concentration of Levothyroxine. Management: Administer oral/enteral levothyroxine at least 4 hours before administration of sucroferric oxyhydroxide. No interaction is anticipated with parenteral levothyroxine administration. Risk D: Consider therapy modification

Theophylline Derivatives: Thyroid Products may increase the metabolism of Theophylline Derivatives. Exceptions: Dyphylline. Risk C: Monitor therapy

Tricyclic Antidepressants: Thyroid Products may enhance the arrhythmogenic effect of Tricyclic Antidepressants. Thyroid Products may enhance the stimulatory effect of Tricyclic Antidepressants. Risk C: Monitor therapy

Vitamin K Antagonists (eg, warfarin): Thyroid Products may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Food Interactions

Taking levothyroxine with enteral nutrition may cause reduced bioavailability and may lower serum thyroxine levels leading to signs or symptoms of hypothyroidism. Soybean flour (infant formula), soy, grapefruit juice, espresso coffee, cottonseed meal, walnuts, calcium, iron, and dietary fiber may interfere with absorption of levothyroxine from the GI tract. Management: Take in the morning on an empty stomach at least 30 minutes before food. Alternatively, may consistently administer at night 3 to 4 hours after the last meal (AACE/ATA [Garber 2012]; ATA [Jonklaas 2014]). Consider an increase in dose if taken with enteral tube feed. Do not administer within 4 hours of calcium- or iron-containing products.

Test Interactions

T4-binding globulin (TBG): Factors that alter binding in serum (ATA/AACE [Garber 2012]):

Note: T4 is ~99.97% protein bound. Factors that alter protein binding will affect serum total T4 levels; however, measurement of serum free T4 (the metabolically active moiety) has largely replaced serum total T4 for thyroid status assessment.

Conditions/states that increase TBG binding: Pregnancy, hepatitis, porphyria, neonatal state

Medications that increase TBG binding: Estrogens, 5-fluorouracil, heroin, methadone, mitotane, perphenazine, selective estrogen receptor modulators (eg, tamoxifen, raloxifene)

Conditions/states that decrease TBG binding: Hepatic failure, nephrosis, severe illness.

Medications that decrease TBG binding: Androgens, anabolic steroids, glucocorticoids, L-asparaginase, nicotinic acid

Thyroxine (T4) and triiodothyronine (T3): Serum binding inhibitors (ATA/AACE [Garber 2012]):

Medications that inhibit T4 and T3 binding: Carbamazepine, furosemide, free fatty acids, heparin, NSAIDS (variable, transient), phenytoin, salicylates

Thyroid gland hormone: Interference with production and secretion (ATA/AACE [Garber 2012]):

Medications affecting iodine uptake: Amiodarone, iodinated contrast agents, iodine, ethionamide

Medications affecting hormone production: Amiodarone, ethionamide, iodinated contrast agents, iodine, sulfonylureas, sulfonamides, thionamides (carbimazole, methimazole, propylthiouracil),

Medications affecting secretion: Amiodarone, iodinated contrast agents, iodine, lithium

Medications inducing thyroiditis: Alemtuzumab, amiodarone, antiangiogenic agents (lenalidomide, thalidomide), denileukin diftitox, interferon alpha, interleukins, lithium, tyrosine kinase inhibitors (sunitinib, sorafenib)

Medications potentially causing the development of Graves’: Alemtuzumab, interferon alpha, antiretroviral therapy

Medications potentially ameliorating thyroiditis (if autoimmune) or Graves’: Glucocorticoids

Hypothalamic-pituitary axis and TSH: Interference with secretion (ATA/AACE [Garber 2012]):

Medications decreasing TSH secretion: Bexarotene, dopamine, dopaminergic agonists (bromocriptine, cabergoline), glucocorticoids, interleukin-6, metformin, opiates, somatostatin analogues (octreotide, lanreotide), thyroid hormone analogues

Medications increasing TSH secretion: Amphetamine, interleukin 2, metoclopramide, ritonavir, St John's wort

Medications potentially causing hypophysitis: Ipilimumab

Monitoring Parameters

Pediatrics: Monitor closely for under/overtreatment. Undertreatment may decrease intellectual development and linear growth and lead to poor school performance due to impaired concentration and slowed mentation. Overtreatment may adversely affect brain maturation and accelerate bone age (leading to premature closure of the epiphyses and reduced adult height); craniosynostosis has been reported in infants. Perform routine clinical examinations at regular intervals (to assess mental and physical growth and development). Treated children may experience a period of catch-up growth. Monitor TSH and total or free T4 at 2 and 4 weeks after starting treatment, every 1 to 2 months during the first year of life, every 2 to 3 months between ages 1 to 3 years, and every 3 to 12 months thereafter until growth is completed (AAP 2006; ATA [Jonklaas 2014]); repeat tests 2 weeks after any change in dosage.

Adults: Heart rate, blood pressure, clinical signs of hypo- and hyperthyroidism; bone mineral density (particularly with long term use in postmenopausal women)

Primary hypothyroidism: In patients who experience symptomatic improvement following initiation of therapy or dosage adjustment, measure TSH response at 6 weeks and titrate therapy as needed (ATA [Jonklaas 2014]). In those who continue to experience symptoms, consider measuring free T4 (FT4) and TSH at 3 weeks and increasing the dose if FT4 is below normal (Ross 2019e); clinicians should note that the full effect of the dose may not be apparent at 3 weeks as levothyroxine does not achieve steady state until ~6 weeks post-initiation or dosage adjustment. Continue to measure serum TSH (and FT4 if levothyroxine steady state has not yet been achieved) every 3 to 6 weeks and titrate the dose until the TSH concentration is within the goal range (ATA [Jonklaas 2014]; Ross 2019e).

Hypothyroidism in pregnant patients: Clinical decisions in this patient population should rely on trimester- and population-specific reference ranges (ATA [Alexander 2017]). TSH goals should target the lower half of the trimester-specific reference range (or <2.5 milliunits/L when trimester-specific targets are unavailable) (ATA [Alexander 2017]). Patients with or at risk for hypothyroidism should undergo TSH evaluation every 4 weeks until midgestation and at least once near 30 weeks gestation (ATA [Alexander 2017]; De Groot 2012); re-assess TSH 2 to 4 weeks after initiation of therapy or dosage adjustment (ATA [Alexander 2017]). In patients who were initiated on levothyroxine during pregnancy, the necessity of continuing treatment should be evaluated; some patients will not require continued therapy. TSH should be measured 6 weeks after dosage adjustment or discontinuation (ATA [Alexander 2017]).

Postpartum thyroiditis: Evaluate TSH every 2 months following resolution of the thyrotoxic phase of PPT until 1 year following delivery.

Secondary hypothyroidism: Monitor response to treatment with measurement of FT4 concentrations; goal of treatment is to maintain FT4 concentrations in upper half of the reference range (or slightly higher than mid-normal (ATA [Jonklaas 2014]; Ross 2019d).

Reference Range

T4 (thyroxine) serum concentrations: Adults: ~4 to 12 mcg/dL (SI: 51 to 154 nmol/L). Note: Normal range in pregnancy: ~5.5 to 16 mcg/dL (SI: ~71 to 206 nmol/L)

T4 free (free thyroxine; free T4) serum concentrations: Adults: 0.7 to 1.8 ng/dL (SI: 9 to 23 pmol/L). A target range in the mid to upper half of the reference range has been suggested in patients with central hypothyroidism (ES [Fleseriu 2016]).

T3 total (triiodothyronine; total T3) serum concentrations: Adults: 80 to 230 ng/dL (SI: 1.2 to 3.5 nmol/L)

Thyroid-stimulating hormone (TSH) serum concentrations: Adults: Varies by laboratory and assay used; refer to laboratory provided reference range. If an upper and lower limit of normal for a third generation TSH assay is not available, a reference range of 0.45 to 4.12 milliunits/L should be considered (ATA/AACE [Garber 2012]). A higher target range of 4 to 6 milliunits/L has been suggested in patients >70 years of age (ATA [Jonklaas 2014]).

Subclinical hypothyroidism (elevated TSH; free T4 within normal range):

Severe (TSH ≥10 milliunits/L): These patients are at increased risk for heart failure and cardiovascular mortality and should be considered for treatment with L-thyroxine (ATA/AACE [Garber 2012]; ETA [Pearce 2013])

Mild to moderate (TSH 4 to 10 milliunits/L): Decision for when to treat should be tailored to individual patient based on age, symptoms, and cardiovascular risk (ATA/AACE [Garber 2012]; ETA [Pearce 2013])

Advanced Practitioners Physical Assessment/Monitoring

Obtain renal function tests, T3, T4, TSH, and unbound T4 levels; monitor periodically and with dose changes. Monitor periodically and with dose changes. Monitor for hyper/hypothyroidism and adrenal insufficiency. Check blood pressure and heart rate; monitor for worsening cardiovascular disease. Caution patients with diabetes to monitor glucose levels closely (may increase need for oral hypoglycemics or insulin). Obtain bone mineral density in patients on long-term use with post-menopausal women. Assess infants closely for cardiac overload, arrhythmias, or aspiration. Assess pediatric patients closely for over/undertreatment and obtain TSH and total or free T4 at 2 and 4 weeks after starting treatment; every 1 to 2 months for first year of life; every 2 to 3 months during years 1 to 3; every 3 to 12 months until growth completed.

Nursing Physical Assessment/Monitoring

Check labs and report any abnormalities. Monitor vital signs closely, as well as signs of heart disease. Monitor mental and physical growth and development in pediatric patients. Monitor for and instruct patients to report any signs/symptoms of hyperthyroidism (weight loss, nervousness, sweating, tachycardia, insomnia, heat intolerance, palpitations, vomiting, psychosis, fever, seizures, angina, arrhythmias). Instruct patients with diabetes to monitor glucose levels closely (may increase need for oral hypoglycemics or insulin). Instruct patients not to change levothyroxine products without talking to healthcare provider.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral:

Tirosint: 175 mcg, 200 mcg

Capsule, Oral, as sodium:

Tirosint: 13 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg

Solution, Intravenous [preservative free]:

Generic: 100 mcg/5 mL (5 mL); 200 mcg/5 mL (5 mL); 500 mcg/5 mL (5 mL)

Solution, Oral, as sodium:

Tirosint-SOL: 13 mcg/mL (1 mL); 25 mcg/mL (1 mL); 50 mcg/mL (1 mL); 75 mcg/mL (1 mL); 88 mcg/mL (1 mL); 100 mcg/mL (1 mL); 112 mcg/mL (1 mL); 125 mcg/mL (1 mL); 137 mcg/mL (1 mL); 150 mcg/mL (1 mL); 175 mcg/mL (1 mL); 200 mcg/mL (1 mL)

Solution Reconstituted, Intravenous, as sodium [preservative free]:

Generic: 100 mcg (1 ea); 200 mcg (1 ea); 500 mcg (1 ea)

Tablet, Oral, as sodium:

Euthyrox: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg [contains corn starch]

Levoxyl: 25 mcg [scored; contains fd&c yellow #6 aluminum lake]

Levoxyl: 50 mcg [scored]

Levoxyl: 75 mcg [scored; contains fd&c blue #1 aluminum lake]

Levoxyl: 88 mcg [scored; contains fd&c blue #1 aluminum lake, fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake]

Levoxyl: 100 mcg [scored; contains fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake]

Levoxyl: 112 mcg [scored; contains fd&c red #40 aluminum lake, fd&c yellow #6 aluminum lake]

Levoxyl: 125 mcg [scored; contains fd&c red #40 aluminum lake, fd&c yellow #10 aluminum lake]

Levoxyl: 137 mcg, 150 mcg [scored; contains fd&c blue #1 aluminum lake]

Levoxyl: 175 mcg [scored; contains fd&c blue #1 aluminum lake, fd&c yellow #10 aluminum lake]

Levoxyl: 200 mcg [scored; contains fd&c yellow #10 aluminum lake]

Synthroid: 25 mcg [scored; contains fd&c yellow #6 aluminum lake]

Synthroid: 50 mcg [scored; contains corn starch]

Synthroid: 75 mcg [scored; contains corn starch, fd&c blue #2 aluminum lake, fd&c red #40 aluminum lake]

Synthroid: 88 mcg [scored; contains corn starch, fd&c blue #1 aluminum lake, fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake]

Synthroid: 100 mcg [scored; contains corn starch, fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake]

Synthroid: 112 mcg [scored; contains corn starch]

Synthroid: 125 mcg [scored; contains corn starch, fd&c blue #1 aluminum lake, fd&c red #40 aluminum lake, fd&c yellow #6 aluminum lake]

Synthroid: 137 mcg [scored; contains fd&c blue #1 aluminum lake]

Synthroid: 150 mcg [scored; contains fd&c blue #2 aluminum lake]

Synthroid: 175 mcg [scored; contains fd&c blue #1 aluminum lake]

Synthroid: 200 mcg [scored; contains fd&c red #40 aluminum lake]

Synthroid: 300 mcg [scored; contains fd&c blue #1 aluminum lake, fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake]

Unithroid: 25 mcg [contains fd&c yellow #6 aluminum lake]

Unithroid: 50 mcg

Unithroid: 75 mcg [contains fd&c blue #2 aluminum lake, fd&c red #40 aluminum lake]

Unithroid: 88 mcg [contains fd&c blue #1 aluminum lake, fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake]

Unithroid: 100 mcg [contains fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake]

Unithroid: 112 mcg

Unithroid: 125 mcg [contains fd&c blue #1 aluminum lake, fd&c red #40 aluminum lake, fd&c yellow #6 aluminum lake]

Unithroid: 137 mcg [contains fd&c blue #1 aluminum lake]

Unithroid: 150 mcg [contains fd&c blue #2 aluminum lake]

Unithroid: 175 mcg [contains fd&c blue #1 aluminum lake]

Unithroid: 200 mcg [contains fd&c red #40 aluminum lake]

Unithroid: 300 mcg [contains fd&c blue #1 aluminum lake, fd&c yellow #10 (quinoline yellow), fd&c yellow #6 aluminum lake]

Unithroid Direct: 25 mcg [DSC] [contains fd&c yellow #6 aluminum lake]

Unithroid Direct: 50 mcg [DSC]

Unithroid Direct: 75 mcg [DSC], 88 mcg [DSC] [contains fd&c blue #1 aluminum lake, fd&c blue #2 aluminum lake, fd&c red #40 aluminum lake, fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake]

Unithroid Direct: 100 mcg [DSC] [contains fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake]

Unithroid Direct: 112 mcg [DSC]

Unithroid Direct: 125 mcg [DSC] [contains fd&c blue #1 aluminum lake, fd&c red #40 aluminum lake, fd&c yellow #6 aluminum lake]

Unithroid Direct: 150 mcg [DSC] [contains fd&c blue #2 aluminum lake]

Unithroid Direct: 175 mcg [DSC] [contains fd&c blue #1 aluminum lake]

Unithroid Direct: 200 mcg [DSC] [contains fd&c red #40 aluminum lake]

Unithroid Direct: 300 mcg [DSC] [contains fd&c blue #1 aluminum lake, fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake]

Generic: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 300 mcg

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution Reconstituted, Injection, as sodium:

Synthroid: 500 mcg (1 ea, 10 ea)

Generic: 200 mcg (1 ea); 500 mcg (1 ea)

Tablet, Oral, as sodium:

Euthyrox: 25 mcg [contains fd&c red #40 aluminum lake, fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake]

Euthyrox: 50 mcg

Euthyrox: 75 mcg [contains fd&c blue #1 aluminum lake, fd&c blue #2 aluminum lake, fd&c red #40 aluminum lake, fd&c yellow #6 aluminum lake]

Euthyrox: 88 mcg [contains fd&c blue #2 aluminum lake, fd&c yellow #5 aluminum lake]

Euthyrox: 100 mcg [contains fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake]

Euthyrox: 112 mcg

Euthyrox: 125 mcg [contains fd&c blue #1 aluminum lake, fd&c blue #2 aluminum lake, fd&c red #40 aluminum lake, fd&c yellow #5 aluminum lake, fd&c yellow #6 aluminum lake]

Euthyrox: 137 mcg [contains fd&c blue #1 aluminum lake]

Euthyrox: 150 mcg, 175 mcg [contains fd&c blue #2 aluminum lake]

Euthyrox: 200 mcg

Euthyrox: 300 mcg [contains fd&c blue #1 aluminum lake, fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake]

Synthroid: 25 mcg [contains fd&c yellow #6 (sunset yellow)]

Synthroid: 50 mcg

Synthroid: 75 mcg [contains fd&c blue #2 (indigotine), fd&c red #40]

Synthroid: 88 mcg [contains brilliant blue fcf (fd&c blue #1), fd&c yellow #10 (quinoline yellow), fd&c yellow #6 (sunset yellow)]

Synthroid: 100 mcg [contains fd&c yellow #10 (quinoline yellow), fd&c yellow #6 (sunset yellow)]

Synthroid: 112 mcg

Synthroid: 125 mcg [contains brilliant blue fcf (fd&c blue #1), fd&c red #40, fd&c yellow #6 (sunset yellow)]

Synthroid: 137 mcg [contains brilliant blue fcf (fd&c blue #1)]

Synthroid: 150 mcg [contains fd&c blue #2 (indigotine)]

Synthroid: 175 mcg [contains brilliant blue fcf (fd&c blue #1)]

Synthroid: 200 mcg [contains fd&c red #40]

Synthroid: 300 mcg [contains brilliant blue fcf (fd&c blue #1), fd&c yellow #10 (quinoline yellow), fd&c yellow #6 (sunset yellow)]

Generic: 50 mcg, 100 mcg, 150 mcg, 200 mcg, 300 mcg [DSC]

Anatomic Therapeutic Chemical (ATC) Classification

• H03AA01

Generic Available (US)

May be product dependent

Pricing: US

Capsules (Tirosint Oral)

13 mcg (per each): $5.33

25 mcg (per each): $5.33

50 mcg (per each): $5.33

75 mcg (per each): $5.33

88 mcg (per each): $5.33

100 mcg (per each): $5.33

112 mcg (per each): $5.33

125 mcg (per each): $5.33

137 mcg (per each): $5.33

150 mcg (per each): $5.33

175 mcg (per each): $5.33

200 mcg (per each): $5.33

Solution (Levothyroxine Sodium Intravenous)

100 mcg/5 mL (per mL): $26.61

200 mcg/5 mL (per mL): $53.21

500 mcg/5 mL (per mL): $133.03

Solution (Tirosint-SOL Oral)

13 mcg/mL (per mL): $5.33

25 mcg/mL (per mL): $5.33

50 mcg/mL (per mL): $5.33

75 mcg/mL (per mL): $5.33

88 mcg/mL (per mL): $5.33

100 mcg/mL (per mL): $5.33

112 mcg/mL (per mL): $5.33

125 mcg/mL (per mL): $5.33

137 mcg/mL (per mL): $5.33

150 mcg/mL (per mL): $5.33

175 mcg/mL (per mL): $5.33

200 mcg/mL (per mL): $5.33

Solution (reconstituted) (Levothyroxine Sodium Intravenous)

100 mcg (per each): $110.17 - $149.64

200 mcg (per each): $228.42 - $264.00

500 mcg (per each): $570.78 - $633.49

Tablets (Euthyrox Oral)

25 mcg (per each): $0.44

50 mcg (per each): $0.50

75 mcg (per each): $0.55

88 mcg (per each): $0.56

100 mcg (per each): $0.56

112 mcg (per each): $0.65

125 mcg (per each): $0.66

137 mcg (per each): $0.67

150 mcg (per each): $0.68

175 mcg (per each): $0.81

200 mcg (per each): $0.81

Tablets (Levo-T Oral)

25 mcg (per each): $0.44

50 mcg (per each): $0.50

75 mcg (per each): $0.55

88 mcg (per each): $0.56

100 mcg (per each): $0.56

112 mcg (per each): $0.65

125 mcg (per each): $0.66

137 mcg (per each): $0.67

150 mcg (per each): $0.68

175 mcg (per each): $0.81

200 mcg (per each): $0.81

300 mcg (per each): $1.04

Tablets (Levothyroxine Sodium Oral)

25 mcg (per each): $0.44 - $0.46

50 mcg (per each): $0.50 - $0.52

75 mcg (per each): $0.55 - $0.57

88 mcg (per each): $0.56 - $0.70

100 mcg (per each): $0.56 - $0.59

112 mcg (per each): $0.65 - $0.81

125 mcg (per each): $0.66 - $0.69

137 mcg (per each): $0.67

150 mcg (per each): $0.68 - $0.71

175 mcg (per each): $0.81 - $1.01

200 mcg (per each): $0.81

300 mcg (per each): $1.09

Tablets (Levoxyl Oral)

25 mcg (per each): $0.84

50 mcg (per each): $0.95

75 mcg (per each): $1.05

88 mcg (per each): $1.07

100 mcg (per each): $1.07

112 mcg (per each): $1.24

125 mcg (per each): $1.26

137 mcg (per each): $1.28

150 mcg (per each): $1.30

175 mcg (per each): $1.54

200 mcg (per each): $1.54

Tablets (Synthroid Oral)

25 mcg (per each): $1.56

50 mcg (per each): $1.56

75 mcg (per each): $1.56

88 mcg (per each): $1.56

100 mcg (per each): $1.56

112 mcg (per each): $1.56

125 mcg (per each): $1.56

137 mcg (per each): $1.56

150 mcg (per each): $1.56

175 mcg (per each): $1.56

200 mcg (per each): $1.56

300 mcg (per each): $1.56

Tablets (Unithroid Oral)

25 mcg (per each): $3.67

50 mcg (per each): $3.67

75 mcg (per each): $3.67

88 mcg (per each): $3.68

100 mcg (per each): $3.69

112 mcg (per each): $3.70

125 mcg (per each): $3.70

137 mcg (per each): $3.71

150 mcg (per each): $3.71

175 mcg (per each): $3.71

200 mcg (per each): $3.72

300 mcg (per each): $3.72

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Levothyroxine (T4) is a synthetic form of thyroxine, an endogenous hormone secreted by the thyroid gland. T4 is converted to its active metabolite, L-triiodothyronine (T3). Thyroid hormones (T4 and T3) then bind to thyroid receptor proteins in the cell nucleus and exert metabolic effects through control of DNA transcription and protein synthesis; involved in normal metabolism, growth, and development; promotes gluconeogenesis, increases utilization and mobilization of glycogen stores, and stimulates protein synthesis, increases basal metabolic rate

Pharmacodynamics/Kinetics

Onset of action: Oral: 3 to 5 days; peak therapeutic effect may require 4 to 6 weeks; IV: Within 6 to 8 hours

Absorption: Oral: Erratic (40% to 80% [per manufacturer]); reported bioavailability in fasting state is 79% to 81% (Dickerson 2010; Fish 1987). Absorption may be decreased by age and specific foods and drugs.

Protein binding: >99% bound to plasma proteins including thyroxine-binding globulin, thyroxine-binding prealbumin, and albumin

Metabolism: Hepatic to triiodothyronine (T3; active); ~80% thyroxine (T4) deiodinated in kidney and periphery; glucuronidation/conjugation also occurs; undergoes enterohepatic recirculation

Time to peak, serum: 2 to 4 hours

Half-life elimination: Euthyroid: 6 to 7 days; Hypothyroid: 9 to 10 days; Hyperthyroid: 3 to 4 days

Excretion: Urine (major route of elimination; decreases with age); feces (~20%)

Local Anesthetic/Vasoconstrictor Precautions

No precautions with vasoconstrictor are necessary if patient is well controlled with levothyroxine

Effects on Dental Treatment

No significant effects or complications reported

Effects on Bleeding

No information available to require special precautions

Related Information

• Narrow Therapeutic Index Drugs
• Oral Medications That Should Not Be Crushed or Altered

Pharmacotherapy Pearls

For purposes of conversion, levothyroxine sodium (T4) 100 mcg is approximately equivalent to desiccated thyroid 60 to 65 mg (1 grain), liothyronine sodium (T3) 25 mcg, or liotrix 12.5 mcg T3/50 mcg T4.

Index Terms

L-Thyroxine Sodium; Levothroid; Levothyroxine Sodium; T4; Tirosint-Sol

References

Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum [published correction appears in Thyroid. 2017;27(9):1212]. Thyroid. 2017;27(3):315-389. doi: 10.1089/thy.2016.0457.[PubMed 28056690]

American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on Genetics, American Thyroid Association, et al. Update of Newborn Screening and Therapy for Congenital Hypothyroidism. Pediatrics. 2006;117(6):2290-2303.[PubMed 16740880]

American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 148: thyroid disease in pregnancy. Obstet Gynecol. 2015;125(4):996-1005. doi: 10.1097/01.AOG.0000462945.27539.93.[PubMed 25798985]

Burman KD. Postpartum thyroiditis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 9, 2019.

Carswell JM, Gordon JH, Popovsky E, Hale A, Brown RS. Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism. J Clin Endocrinol Metab. 2013;98(2):610-617. doi: 10.1210/jc.2012-3125.[PubMed 23264396]

Cytomel (liothyronine) [prescribing information]. New York, NY: Pfizer Inc; June 2016.

de Groot JW, Zonnenberg BA, Plukker JT, et al, "Imatinib Induces Hypothyroidism in Patients Receiving Levothyroxine," Clin Pharmacol Ther, 2005, 78(4):433-8.[PubMed 16198662]

De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(8):2543-2565.[PubMed 22869843]

Dickerson DN, Maish GO 3rd, Minard G, et al, “Clinical Relevancy of Levothyroxine – Continuous Enteral Nutrition Interaction,” Nutr Clin Pract, 2010, 25(6):646-52.[PubMed 21139130]

Eltroxin (levothyroxine) [product monograph]. Toronto, Ontario, Canada: Aspen Pharmacare Canada Inc; January 2020.

Euthyrox (levothyroxine sodium) [prescribing information]. Honey Brook, PA: Provell Pharmaceuticals, LLC; September 2018.

Farwell AP. Sporadic Painless, Painful Subacute and Acute Infectious Thyroiditis. In: Braverman LE, Cooper DS. Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013:418-422.

Feller M, Snel M, Moutzouri E, et al. Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism: a systematic review and meta-analysis. JAMA. 2018;320(13):1349-1359. doi: 10.1001/jama.2018.13770.[PubMed 30285179]

Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med. 1987;316(13):764-770.[PubMed 3821822]

Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3888-3921. doi: 10.1210/jc.2016-2118.[PubMed 27736313]

Francis GL, Waguespack SG, Bauer AJ, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;25(7):716-759.[PubMed 25900731]

Garber KR, Cobin RH, Gharib H, et al; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association [published correction appears in Endocr Pract. 2013;19(1):175]. Endocr Pract. 2012;18(6):988-1028.[PubMed 23246686]

Gharib H, Papini E, Garber JR, et al; AACE/ACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules--2016 update. Endocr Pract. 2016;22(5):622-639. doi: 10.4158/EP161208.GL.[PubMed 27167915]

Gupta VD. Stability of levothyroxine sodium injection in polypropylene syringes. Int J Pharm Compound. 2000;4(6):482-483.[PubMed 23981741]

Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. doi: 10.1089/thy.2015.0020.[PubMed 26462967]

Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993;168(5):1393-1399.[PubMed 8498418]

Jonklaas J, Bianco AC, Bauer AJ, et al; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670-1751.[PubMed 25266247]

Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. Nelson' s Textbook of Pediatrics. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.

Kotloff RM, Blosser S, Fulda GJ, et al; Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Donor Management Task Force. Management of the potential organ donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Consensus Statement. Crit Care Med. 2015;43(6):1291-1325. doi: 10.1097/CCM.0000000000000958.[PubMed 25978154]

Kumar L. Brain death and care of the organ donor. J Anaesthesiol Clin Pharmacol. 2016;32(2):146-152. doi: 10.4103/0970-9185.168266.[PubMed 27275040]

Lee DY, Seok J, Jeong WJ, Ahn SH. Prediction of thyroid hormone supplementation after thyroid lobectomy. J Surg Res. 2015;193(1):273-278. doi: 10.1016/j.jss.2014.07.003.[PubMed 25088372]

Léger J, Olivieri A, Donaldson M, et al; ESPE-PES-SLEP-JSPE-APEG-APPES-ISPAE; Congenital Hypothyroidism Consensus Conference Group. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. Horm Res Paediatr. 2014;81(2):80-103. doi: 10.1159/000358198.[PubMed 24662106]

Levothyroxine for injection [product monograph]. Blainville, Quebec, Canada: AVIR Pharmaceuticals Inc; July 2017.

Levothyroxine for injection [prescribing information]. Chestnut Ridge, NY: Par Pharmaceuticals; August 2016.

Levothyroxine sodium for injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA LLC; April 2019.

Levoxyl (levothyroxine sodium) [prescribing information]. New York, NY: Pfizer; December 2018.

Levoxyl tablets (levothyroxine) [prescribing information]. New York, NY: Pfizer Inc.; December 2018.

Macdonald PS, Aneman A, Bhonagiri D, et al. A systematic review and meta-analysis of clinical trials of thyroid hormone administration to brain dead potential organ donors. Crit Care Med. 2012;40(5):1635-1644. doi: 10.1097/CCM.0b013e3182416ee7.[PubMed 22511141]

Manzullo EF, Ross DS. Nonthyroid surgery in the patient with thyroid disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed April 2, 2019.

Mariani LH, Berns JS. The renal manifestations of thyroid disease. J Am Soc Nephrol. 2012;23(1):22-26. doi: 10.1681/ASN.2010070766.[PubMed 22021708]

Nakagawa TA, "Updated Pediatric Donor Management and Dosing Guidelines," 2008. Available at http://www.natco1.org/prof_development/documents/FINALNATCOPedDonorManagementGuidelines_Jan08.pdf. Last accessed June 2012.

Novitzky D, Mi Z, Sun Q, Collins JF, Cooper DK. Thyroid hormone therapy in the management of 63,593 brain-dead organ donors: a retrospective analysis. Transplantation. 2014;98(10):1119-1127. doi: 10.1097/TP.0000000000000187.[PubMed 25405914]

Novitzky D, Mi Z, Collins JF, Cooper DK. Increased procurement of thoracic donor organs after thyroid hormone therapy. Semin Thorac Cardiovasc Surg. 2015;27(2):123-132. doi: 10.1053/j.semtcvs.2015.06.012.[PubMed 26686437]

Parle JV, Maisonneuve P, Sheppard MC, et al, “Prediction of All-Cause and Cardiovascular Mortality in Elderly People from One Low Serum Thyrotropin Result: A 10-year Cohort Study,” Lancet, 2001, 358(9285):861-5.[PubMed 11567699]

Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA guideline: management of subclinical hypothyroidism. Eur Thyroid J. 2013;2(4):215-228.[PubMed 24783053]

Roos A, Linn-Rasker SP, van Domburg RT, Tijssen JP, Berghout A. The starting dose of levothyroxine in primary hypothyroidism treatment: a prospective, randomized, double-blind trial [published correction appears in Arch Intern Med. 2005;165(19):2227]. Arch Intern Med. 2005;165(15):1714-1720. doi: 10.1001/archinte.165.15.1714.[PubMed 16087818]

Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation. 2003a;75(4):482-487.[PubMed 12605114]

Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation. 2003b;75(8):1336-1341.[PubMed 12717226]

Ross DS. Central hypothyroidism. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 11, 2020.

Ross DS. Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 25, 2019.

Ross DS. Myxedema coma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 25, 2019.

Ross DS. Subclinical hypothyroidism in nonpregnant adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed April 2, 2019d.

Ross DS. Treatment of primary hypothyroidism in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 25, 2019.

Salim A, Martin M, Brown C, et al. Using thyroid hormone in brain-dead donors to maximize the number of organs available for transplantation. Clin Transplant. 2007;21(3):405-409.[PubMed 17488392 ]

Santini F, Pinchera A, Marsili A, et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab. 2005;90(1):124-127. doi: 10.1210/jc.2004-1306.[PubMed 15483074]

Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen. JAMA. 1994;271(16):1245-1249.[PubMed 7848399]

Selva KA, Mandel SH, Rien L, et al. Initial Treatment Dose of L-thyroxine in Congenital Hypothyroidism. J Pediatr. 2002;141(6):786-792.[PubMed 12461494]

Stagnaro-Green A, Abalovich M, Alexander E, et al; American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21(10):1081-1125. doi: 10.1089/thy.2011.0087.[PubMed 21787128]

Strong DK, Decarie D, and Ensom MHH, “Stability of Levothyroxine in Sodium Chloride for IV Administration,” Can J Hosp Pharm, 2010, 63(6):437-43.

Syed Q, Hendler KT, Koncilja K. The impact of aging and medical status on dysgeusia. Am J Med. 2016;129(7):753.[PubMed 26899755]

Synthroid (levothyroxine) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2018.

Synthroid (levothyroxine) [product monograph]. St-Laurent, Quebec, Canada: BGP Pharma ULC; May 2015.

Tirosint (levothyroxine) [prescribing information]. Cranford, NJ: Akrimax Pharmaceuticals; June 2018.

Tirosint-Sol (levothyroxine) [US prescribing information]. Pambio-Noranco, Switzerland: IBSA Institut Biochimique SA; June 2018.

Tuttle RM. Differentiated thyroid cancer: Overview of management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed April 2, 2019.

Unithroid (levothyroxine sodium) [prescribing information]. Bridgewater, NJ: Amneal Specialty; June 2019.

van Wassenaer AG, Stulp MR, Valianpour F, et al, The quantity of thyroid hormone in human milk Is too low to influence plasma thyroid hormone levels in the very preterm infant. Clin Endocrinol (Oxf). 2002;56(5):621-627.[PubMed 12030913]

World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/

Zeitler P, Solberg P, and Pharmacy and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society, "Food and Levothyroxine Administration in Infants and Children," J Pediatr, 2010, 157(1):13-14.[PubMed 20547262]

Zuppa AF, Nadkarni V, Davis L, et al, "The Effect of a Thyroid Hormone Infusion on Vasopressor Support in Critically Ill Children With Cessation of Neurologic Function," Crit Care Med, 2004, 32(11):2318-22.[PubMed 15640648]

Brand Names: International

Accu-Thyrox (RO); Berlthyrox (DE); Cynocuatro (MX); Droxine (NZ); Eferox (BH, QA); Elthyro (TH); Eltroxin (AE, AU, BD, BF, BH, BJ, BM, BZ, CH, CI, CY, CZ, DK, ET, GB, GH, GM, GN, GY, HK, IE, IL, IQ, IR, JO, JP, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, NE, NG, OM, PH, PK, QA, SA, SC, SD, SL, SN, SR, SY, TH, TN, TW, TZ, UG, YE, ZA, ZM, ZW); Eurolev (PH); Euthirox (UA); Euthyrox (AE, AR, AT, BE, BG, BH, BR, CH, CN, CY, CZ, DE, EE, EG, HR, HU, ID, IS, JO, KW, LB, LU, LV, MY, PH, PL, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TZ, VE); Eutirox (BB, BS, CL, CR, CU, DO, ES, GT, HN, IT, JM, MX, NI, NL, PA, PE, SV, TT); Eutroxsig (AU, NZ); Levaxin (SE); Levhexal (MX); Levothyrox (FR); Levotirox (IT); Levotiroxina (EC); Narval (UY); Oroxine (AU, IE, MY); Pondtroxin (TH); Synox (IN); Synroid (BD); Synthroid (BH, BR, CO, KR, KW, NZ); Synthyroxine (KR); T4 (PY); T4KP (TH); Thevier (BE, DE); Thormon (BD); Throid (BD); Thydin (PH); Thynor (BD); Thyradin S (JP); Thyrax (BE, CZ, ID, PT); Thyrax Duotab (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM); Thyrex (AT); Thyro-4 (GR); Thyroid-S (TW); Thyromega (LK); Thyronorm (LK); Thyrosit (TH); Thyrox (LK); Thyroxin (FI); Thyvex (LK); Tiroidine (MX); Tiroxin (CO, EC); Tyraq (HR); Tyraxin (EG); Zaliana (PH)

Last Updated 3/28/20